(June 30, 2023, 1:04 PM EDT) -- WASHINGTON, D.C. — A bid by a patent owner to substitute nine claims of a botulinum toxin patent following adverse post-grant review (PGR) proceedings was properly rejected by the Patent Trial and Appeal Board, the Federal Circuit U.S. Court of Appeals found....